clinical trial · NCT05444556
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
Eli Lilly and Company·phase1·completed·n = 113
HealthyImlunestrantRepaglinideOmeprazoleDextromethorphanQuinidineRosuvastatinDigoxin
brief summary
The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and tolerability of imlunestrant will be investigated in female healthy participants of non-childbearing potential. The study will last approximately up to 32 days for each participant excluding the screening period.
started
Jul 7, 2022
primary completion
Nov 2, 2022
completion
Nov 2, 2022
last updated
Dec 12, 2025
official title
The Effect of Imlunestrant on CYP2C8, CYP2C19, CYP2D6, P-gp, and BCRP Activity and the Effect of P-gp Inhibition on Imlunestrant Pharmacokinetics in Healthy Women of Non-childbearing Potential
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol